SCHEMBL18005241

SCHEMBL18005241

N#Cc1[nH]nnc1-c1csc(-c2ccsc2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK5 Q00535 1/20 0.40
▸ CDK5R1 Q15078 1/20 0.40
▸ CDC25A P30304 1/20 0.37
▸ CDC25B P30305 1/20 0.37
▸ CDC25C P30307 1/20 0.37
▸ ADORA1 P30542 3/20 0.35
▸ ADORA2A P29274 2/20 0.35
▸ PIM1 P11309 1/20 0.33
▸ KMT2A Q03164 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ PDE3A Q14432 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ LRRK2 Q5S007 1/20 0.31
▸ EIF4E P06730 1/20 0.31
▸ AR P10275 2/20 0.30
▸ FLT4 P35916 1/20 0.30
▸ MAPK8 P45983 1/20 0.30
▸ MAPK9 P45984 1/20 0.30
▸ CSNK2A1 P68400 1/20 0.30
▸ DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18005982 0.84 KMT2A (0.47) CDK5CDK5R1CDC25ACDC25BCDC25C
SCHEMBL18005024 0.83 CDC25A (0.55) CDC25ACDC25BCDC25CKMT2AMEN1
SCHEMBL18005984 0.82 RAB9A (0.46) CDC25ACDC25BCDC25CKMT2AMEN1
SCHEMBL18005019 0.82 RAB9A (0.49) CDC25ACDC25BCDC25CADORA1KMT2A
SCHEMBL18005014 0.82 KDM4E (0.49) CDK5CDK5R1CDC25ACDC25BCDC25C
SCHEMBL16399142 0.82 KDM4E (0.49) CDC25ACDC25BCDC25CADORA1KMT2A
SCHEMBL18005961 0.82 ADORA1 (0.42) CDK5CDK5R1ADORA1ADORA2AALDH1A1
SCHEMBL18005200 0.80 PIM1 (0.38) CDC25ACDC25BCDC25CADORA1ADORA2A
SCHEMBL18005017 0.80 CYP1A1 (0.35) CDC25ACDC25BCDC25CADORA1ADORA2A
SCHEMBL18005007 0.80 CYP1A1 (0.35) CDK5CDK5R1CDC25ACDC25BCDC25C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 CDK5 1268/4885CDK5R1 1059/4885CDC25A 393/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 CDK5 1268/4885CDK5R1 1059/4885CDC25A 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback